Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Systematic review highlights resource constraints affecting overall survival in multiple myeloma, suggesting ASCT improves outcomes.

Overall survival for patients receiving autologous stem cell transplantation was 62% over 2.5-12.5 years.
Bortezomib-based regimens showed better survival outcomes compared to thalidomide-based therapies, reducing the risk by 27%.
The study assessed 37 eligible studies across regions, revealing significant heterogeneity in treatment outcomes.
Comparative analyses indicated ASCT had significantly superior 5-year survival rates compared to conventional chemotherapy.

Almasri et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark